Pfizer (PFE) : Net money flow in Pfizer (PFE) was negative ($9.94 million) and the inflow of money on uptick was $44.74 million, whereas, the outflow of money on downticks amounted to $54.68 million on Wednesday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.82. The block trades show that the large investors, were aggressive sellers in the stock. The total value of block trades on upticks was only $0.73 million. On the other hand, the total value of block trades done on downticks was $10.45 million. The ratio of uptick to downtick block trades was 0.07. The money flow in block trades was negative ($9.72). Pfizer (PFE) gained $0.09 cent during the day and reached $33.92, a gain of 0.25% over the previous day.
Pfizer Inc. has lost 0.85% in the last five trading days and dropped 3.19% in the last 4 weeks. Pfizer Inc. has dropped 2.11% during the last 3-month period . Year-to-Date the stock performance stands at 8.2%.
Pfizer (PFE) : The consensus on Pfizer (PFE) based on 13 analyst recommendation on the company stock is 1.92, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 6 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Pfizer (NYSE:PFE): The stock opened at $33.85 and touched an intraday high of $34 on Wednesday. During the day, the stock corrected to an intraday low of $33.69, however, the bulls stepped in and pushed the price higher to close in the green at $33.99 with a gain of 0.47% for the day. The total traded volume for the day was 14,307,758. The stock had closed at $33.83 in the previous trading session.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.